Intracellular nucleic acid detection in autoimmunity

Annual Review of Immunology

Volumn 35, Issue , 2017, Pages 313-336

  Crowl, John T ^a   Gray, Elizabeth E ^a   Pestal, Kathleen ^a   Volkman, Hannah E ^a   Stetson, Daniel B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Aicardi Gouti res syndrome; CGAS STING; RIG I like receptors; Systemic lupus erythematosus; Toll like receptors; Type I interferons

Indexed keywords

ADAR1 PROTEIN; ANTIVIRUS AGENT; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; NUCLEIC ACID; PROTEIN; RIBONUCLEASE; RIBONUCLEASE H2; SAMHD1 PROTEIN; UNCLASSIFIED DRUG; INTERFERON; TOLL LIKE RECEPTOR;

AICARDI GOUTIERES SYNDROME; ALLELE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; GENE MUTATION; HUMAN; INNATE IMMUNITY; NONHUMAN; NUCLEIC ACID ANALYSIS; NUCLEIC ACID METABOLISM; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; IMMUNOLOGY; METABOLISM; NERVOUS SYSTEM MALFORMATION; NEUROLOGIC DISEASE; VIRUS INFECTION;

ANIMALS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; AUTOIMMUNITY; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; NERVOUS SYSTEM MALFORMATIONS; NUCLEIC ACIDS; TOLL-LIKE RECEPTORS; VIRUS DISEASES;

EID: 85018275878     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-051116-052331     Document Type: Review

References (169)

1. Burnet FMS. 1969. Self and Not-Self. Melbourne, Aust.: Melbourne Univ. Press
2. Janeway CA Jr. 1989. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54(Part 1):1-13
3. Barbalat R, Ewald SE, Mouchess ML, BartonGM. 2011. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29:185-214
4. Goubau D, Deddouche S, Reis ESC. 2013. Cytosolic sensing of viruses. Immunity 38:855-69
5. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-45
6. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. 2001. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413:732-38
7. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, et al. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196-200
8. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, et al. 2004. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303:1526-29
9. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529-31
10. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, et al. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. PNAS 101:5598-603
11. Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors. Annu. Rev. Immunol. 21:335-76
12. Iwasaki A, Medzhitov R. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5:987-95
13. Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, et al. 2006. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol. 7:156-64
14. Lee BL, Moon JE, Shu JH, Yuan L, Newman ZR, et al. 2013. UNC93B1mediates differential trafficking of endosomal TLRs. eLife 2:e00291
15. Miyake K, Shibata T, Ohto U, Shimizu T. 2017. Emerging roles of the processing of nucleic acids and Toll-like receptors in innate immune responses to nucleic acids. J. Leukoc. Biol. 101:135-42
16. Barton GM, Kagan JC, Medzhitov R. 2006. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 7:49-56
17. Mouchess ML, Arpaia N, Souza G, Barbalat R, Ewald SE, et al. 2011. Transmembrane mutations in Toll-like receptor 9 bypass the requirement for ectodomain proteolysis and induce fatal inflammation. Immunity 35:721-32
18. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi GP, et al. 2008. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456:658-62
19. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, et al. 2005. Spatiotemporal regulation ofMyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434:1035-40
20. Pichlmair A, Reis e Sousa C. 2007. Innate recognition of viruses. Immunity 27:370-83
21. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, et al. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603-7
22. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25:417-28
23. Teichmann LL, Schenten D, Medzhitov R, Kashgarian M, Shlomchik MJ. 2013. Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity 38:528-40
24. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, et al. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-37
25. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, et al. 2006. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314:994-97
26. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, et al. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314:997-1001
27. Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T, et al. 2014. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5′-diphosphates. Nature 514:372-75
28. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101-5
29. Seth RB, Sun L, Ea CK, Chen ZJ. 2005. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF 3. Cell 122:669-82
30. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, et al. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167-72
31. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. 2005. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 19:727-40
32. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, et al. 2005. IPS-1, an adaptor triggering RIG-Iand Mda5-mediated type I interferon induction. Nat. Immunol. 6:981-88
33. Stetson DB, Medzhitov R. 2006. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 24:93-103
34. Ishii KJ, Coban C, Kato H, Takahashi K, Torii Y, et al. 2006. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 7:40-48
35. Sun L, Wu J, Du F, Chen X, Chen ZJ. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339:786-91
36. Wu J, Sun L, Chen X, Du F, Shi H, et al. 2013. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339:826-30
37. Gao P, Ascano M, Wu Y, Barchet W, Gaffney BL, et al. 2013. Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 153:1094-107
38. Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, et al. 2013. cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature 498:380-84
39. Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, et al. 2013. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep. 3:1355-61
40. Ishikawa H, Barber GN. 2008. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455:674-78
41. Zhong B, Yang Y, Li S, Wang YY, Li Y, et al. 2008. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 29:538-50
42. Ishikawa H, Ma Z, Barber GN. 2009. STING regulates intracellular DNA-mediated, type I interferondependent innate immunity. Nature 461:788-92
43. Gao D, Wu J, Wu YT, Du F, Aroh C, et al. 2013. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341:903-6
44. Chen Q, Sun L, Chen ZJ. 2016. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 17:1142-49
45. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. 2005. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204:27-42
46. Marshak-Rothstein A, Rifkin IR. 2007. Immunologically active autoantigens: the role of Toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol. 25:419-41
47. Christensen SR, Shlomchik MJ. 2007. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin. Immunol. 19:11-23
48. Rosen A, Casciola-Rosen L. 2016. Autoantigens as partners in initiation and propagation of autoimmune rheumatic diseases. Annu. Rev. Immunol. 34:395-420
49. Crow YJ. 2011. Type I interferonopathies: a novel set of inborn errors of immunity. Ann. N. Y. Acad. Sci. 1238:91-98
50. de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. 2015. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu. Rev. Immunol. 33:823-74
51. Crow YJ, Manel N. 2015. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat. Rev. Immunol. 15:429-40
52. Roers A, Hiller B, Hornung V. 2016. Recognition of endogenous nucleic acids by the innate immune system. Immunity 44:739-54
53. Aicardi J, Goutieres F. 1984. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann. Neurol. 15:49-54
54. Lebon P, Badoual J, Ponsot G, Goutieres F, Hemeury-Cukier F, Aicardi J. 1988. Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy. J. Neurol. Sci. 84:201-8
55. McGonagle D, McDermott MF. 2006. A proposed classification of the immunological diseases. PLOS Med. 3:e297
56. Masters SL, Simon A, Aksentijevich I, Kastner DL. 2009. Horror Autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27:621-68
57. Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, et al. 2009. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30:875-87
58. Cuadrado E, Vanderver A, Brown KJ, Sandza A, Takanohashi A, et al. 2015. Aicardi-Goutieres syndrome harbours abundant systemic and brain-reactive autoantibodies. Ann. Rheum. Dis. 74:1931-39
59. Stetson DB, Ko JS, Heidmann T, Medzhitov R. 2008. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134:587-98
60. Gall A, Treuting P, Elkon KB, Loo YM, Gale M Jr., et al. 2012. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 36:120-31
61. Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GM, et al. 2015. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am. J. Med. Genet. A 167A:296-312
62. Livingston JH, Crow YJ. 2016. Neurologic phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1,ADAR1, and IFIH1:Aicardi-Goutieres syndrome and beyond. Neuropediatrics 47:355-60
63. Lindahl T, Gally JA, Edelman GM. 1969. Properties of deoxyribonuclease 3 from mammalian tissues. J. Biol. Chem. 244:5014-19
64. Hoss M, Robins P, Naven TJ, Pappin DJ, Sgouros J, Lindahl T. 1999. A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. EMBO J. 18:3868-75
65. Mazur DJ, Perrino FW. 1999. Identification and expression of theTREX1 andTREX2cDNAsequences encoding mammalian 3′→5′ exonucleases. J. Biol. Chem. 274:19655-60
66. Chowdhury D, Beresford PJ, Zhu P, Zhang D, Sung JS, et al. 2006. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol. Cell 23:133-42
67. Mazur DJ, Perrino FW. 2001. Excision of 3′ termini by the Trex1 and TREX2 3′→5′ exonucleases: characterization of the recombinant proteins. J. Biol. Chem. 276:17022-29
68. Lehtinen DA, Harvey S, Mulcahy MJ, Hollis T, Perrino FW. 2008. The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease. J. Biol. Chem. 283:31649-56
69. Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, et al. 2006. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 38:917-20
70. Rice G, Newman WG, Dean J, Patrick T, Parmar R, et al. 2007. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am. J. Hum. Genet. 80:811-15
71. Gray EE, Treuting PM, Woodward JJ, Stetson DB. 2015. Cutting edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi-Goutieres syndrome. J. Immunol. 195:1939-43
72. Gao D, Li T, Li XD, Chen X, Li QZ, et al. 2015. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. PNAS 112:E5699-705
73. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. 2010. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 11:1005-13
74. Beck-Engeser GB, Eilat D, Wabl M. 2011. An autoimmune disease prevented by anti-retroviral drugs. Retrovirology 8:91
75. Yang YG, Lindahl T, Barnes DE. 2007. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131:873-86
76. Ahn J, Ruiz P, Barber GN. 2014. Intrinsic self-DNA triggers inflammatory disease dependent on STING. J. Immunol. 193:4634-42
77. Hasan M, Fermaintt CS, Gao N, Sakai T, Miyazaki T, et al. 2015. Cytosolic nuclease TREX1 regulates oligosaccharyltransferase activity independent of nuclease activity to suppress immune activation. Immunity 43:463-74
78. Crow YJ, Leitch A, Hayward BE, Garner A, Parmar R, et al. 2006. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat. Genet. 38:910-16
79. Perrino FW, Harvey S, Shaban NM, Hollis T. 2009. RNaseH2 mutants that cause Aicardi-Goutieres syndrome are active nucleases. J. Mol. Med. 87:25-30
80. Reijns MA, Rabe B, Rigby RE, Mill P, Astell KR, et al. 2012. Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development. Cell 149:1008-22
81. Hiller B, Achleitner M, Glage S, Naumann R, Behrendt R, Roers A. 2012. Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity. J. Exp. Med. 209:1419-26
82. Mackenzie KJ, Carroll P, Lettice L, Tarnauskaite Z, Reddy K, et al. 2016. Ribonuclease H2 mutations induce a cGAS/STING-dependent innate immune response. EMBO J. 35:831-44
83. Pokatayev V, Hasin N, Chon H, Cerritelli SM, Sakhuja K, et al. 2016. RNase H2 catalytic core Aicardi-Goutieres syndrome-related mutant invokes cGAS-STING innate immune-sensing pathway in mice. J. Exp. Med. 213:329-36
84. Gunther C, Kind B, Reijns MA, Berndt N, Martinez-Bueno M, et al. 2015. Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J. Clin. Investig. 125:413-24
85. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, et al. 2009. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat. Genet. 41:829-32
86. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, et al. 2011. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474:654-57
87. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, et al. 2011. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474:658-61
88. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, et al. 2011. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480:379-82
89. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, et al. 2012. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 13:223-28
90. Beloglazova N, Flick R, Tchigvintsev A, BrownG, Popovic A, et al. 2013. Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction. J. Biol. Chem. 288:8101-10
91. Ryoo J, Choi J, Oh C, Kim S, Seo M, et al. 2014. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat. Med. 20:936-41
92. Choi J, Ryoo J, Oh C, Hwang S, Ahn K. 2015. SAMHD1 specifically restricts retroviruses through its RNase activity. Retrovirology 12:46
93. Ryoo J, Hwang SY, Choi J, Oh C, Ahn K. 2016. SAMHD1, the Aicardi-Goutieres syndrome gene and retroviral restriction factor, is a phosphorolytic ribonuclease rather than a hydrolytic ribonuclease. Biochem. Biophys. Res. Commun. 477:977-81
94. Seamon KJ, Sun Z, Shlyakhtenko LS, Lyubchenko YL, Stivers JT. 2015. SAMHD1 is a single-stranded nucleic acid binding protein with no active site-associated nuclease activity. Nucleic Acids Res. 43:6486-99
95. Antonucci JM, St. Gelais C, de Silva S, Yount JS, Tang C, et al. 2016. SAMHD1-mediated HIV-1 restriction in cells does not involve ribonuclease activity. Nat. Med. 22:1072-74
96. Maelfait J, Bridgeman A, Benlahrech A, Cursi C, Rehwinkel J. 2016. Restriction by SAMHD1 limits cGAS/STING-dependent innate and adaptive immune responses to HIV-1. Cell Rep. 16:1492-501
97. Rehwinkel J, Maelfait J, Bridgeman A, Rigby R, Hayward B, et al. 2013. SAMHD1-dependent retroviral control and escape in mice. EMBO J. 32:2454-62
98. Zhao K, Du J, Han X, Goodier JL, Li P, et al. 2013. Modulation of LINE-1 and Alu/SVA retrotransposition by Aicardi-Goutieres syndrome-related SAMHD1. Cell Rep. 4:1108-15
99. Kretschmer S, Wolf C, Konig N, Staroske W, Guck J, et al. 2015. SAMHD1 prevents autoimmunity by maintaining genome stability. Ann. Rheum. Dis. 74:e17
100. Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, et al. 2014. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood 123:1021-31
101. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, et al. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152:714-26
102. Rice GI, Kasher PR, Forte GM, Mannion NM, Greenwood SM, et al. 2012. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat. Genet. 44:1243-48
103. Bass BL. 2002. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 71:817-46
104. Patterson JB, Samuel CE. 1995. Expression and regulation by interferon of a double-stranded-RNAspecific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol. Cell. Biol. 15:5376-88
105. Hartner JC, Walkley CR, Lu J, Orkin SH. 2009. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat. Immunol. 10:109-15
106. Mannion NM, Greenwood SM, Young R, Cox S, Brindle J, et al. 2014. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 9:1482-94
107. Liddicoat BJ, Piskol R, Chalk AM, Ramaswami G, Higuchi M, et al. 2015. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science 349:1115-20
108. Pestal K, Funk CC, Snyder JM, Price ND, Treuting PM, Stetson DB. 2015. Isoforms of RNA-editing enzymeADAR1independently control nucleic acid sensor MDA5-driven autoimmunity andmulti-organ development. Immunity 43:933-44
109. Kim DD, Kim TT, Walsh T, Kobayashi Y, Matise TC, et al. 2004. WidespreadRNAediting of embedded Alu elements in the human transcriptome. Genome Res. 14:1719-25
110. Goodier JL, Kazazian HH Jr. 2008. Retrotransposons revisited: the restraint and rehabilitation of parasites. Cell 135:23-35
111. Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, et al. 2006. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat. Genet. 38:617-19
112. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, et al. 2009. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41:1228-33
113. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. 2009. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 324:387-89
114. Sutherland A, Davies J, Owen CJ, Vaikkakara S, Walker C, et al. 2007. Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility. J. Clin. Endocrinol. Metab. 92:3338-41
115. Rice GI, del Toro Duany Y, Jenkinson EM, Forte GM, Anderson BH, et al. 2014. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat. Genet. 46:503-9
116. Garneau NL, Wilusz J, Wilusz CJ. 2007. The highways and byways of mRNA decay. Nat. Rev.Mol. Cell Biol. 8:113-26
117. Eckard SC, Rice GI, Fabre A, Badens C, Gray EE, et al. 2014. The SKIV2L RNA exosome limits activation of the RIG-I-like receptors. Nat. Immunol. 15:839-45
118. Fabre A, Charroux B, Martinez-Vinson C, Roquelaure B, Odul E, et al. 2012. SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome. Am. J. Hum. Genet. 90:689-92
119. Kawane K, Fukuyama H, Kondoh G, Takeda J, Ohsawa Y, et al. 2001. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Science 292:1546-49
120. Yoshida H, Okabe Y, Kawane K, Fukuyama H, Nagata S. 2005. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat. Immunol. 6:49-56
121. Okabe Y, Kawane K, Akira S, Taniguchi T, Nagata S. 2005. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J. Exp. Med. 202:1333-39
122. Ahn J, Gutman D, Saijo S, Barber GN. 2012. STING manifests self DNA-dependent inflammatory disease. PNAS 109:19386-91
123. Singleton EB, Merten DF. 1973. An unusual syndrome of widened medullary cavities of the metacarpals and phalanges, aortic calcification and abnormal dentition. Pediatr. Radiol. 1:2-7
124. Jang MA, Kim EK, Now H, Nguyen NT, Kim WJ, et al. 2015. Mutations in DDX58, which encodes RIG-I, cause atypical Singleton-Merten syndrome. Am. J. Hum. Genet. 96:266-74
125. Rutsch F, MacDougall M, Lu C, Buers I, Mamaeva O, et al. 2015. A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome. Am. J. Hum. Genet. 96:275-82
126. Bursztejn AC, Briggs TA, del Toro Duany Y, Anderson BH, O'Sullivan J, et al. 2015. Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1: overlap between Aicardi-Goutieres and Singleton-Merten syndromes. Br. J. Dermatol. 173:1505-13
127. Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, et al. 2014. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 371:507-18
128. Jeremiah N, Neven B, Gentili M, Callebaut I, Maschalidi S, et al. 2014. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J. Clin. Investig. 124:5516-20
129. Konig N, Fiehn C, Wolf C, Schuster M, Cura Costa E, et al. 2017. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann. Rheum. Dis. 76:468-72
130. Kim H, Sanchez GA, Goldbach-Mansky R. 2016. Insights from Mendelian interferonopathies: comparison of CANDLE, SAVI with AGS, monogenic lupus. J. Mol. Med. 94:1111-27
131. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T. 2000. Features of systemic lupus erythematosus in DNase1-deficient mice. Nat. Genet. 25:177-81
132. Yasutomo K, Horiuchi T, Kagami S, Tsukamoto H, Hashimura C, et al. 2001. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 28:313-14
133. Al-Mayouf SM, Sunker A, Abdwani R, Abrawi SA, Almurshedi F, et al. 2011. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat. Genet. 43:1186-88
134. Ozcakar ZB, Foster J 2nd, Diaz-Horta O, Kasapcopur O, Fan YS, et al. 2013. DNASE1L3 mutations in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum. 65:2183-89
135. Sisirak V, Sally B, D'Agati V, Martinez-Ortiz W, Ozcakar ZB, et al. 2016. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell 166:88-101
136. Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, et al. 2011. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat. Genet. 43:127-31
137. An J, Briggs TA, Dumax-Vorzet A, Alarcon-Riquelme ME, Belot A, et al. 2017. Tartrate-resistant acid phosphatase deficiency in the predisposition to systemic lupus erythematosus. Arthritis Rheumatol. 69:131-42
138. Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, et al. 2015. Human intracellular ISG15 prevents interferon-a/βover-amplification and auto-inflammation. Nature 517:89-93
139. Meuwissen ME, Schot R, Buta S, Oudesluijs G, Tinschert S, et al. 2016. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J. Exp. Med. 213:1163-74
140. Daugherty MD, Malik HS. 2012. Rules of engagement: molecular insights from host-virus arms races. Annu. Rev. Genet. 46:677-700
141. Hancks DC, Hartley MK, Hagan C, Clark NL, Elde NC. 2015. Overlapping patterns of rapid evolution in the nucleic acid sensors cGAS and OAS1 suggest a common mechanism of pathogen antagonism and escape. PLOS Genet. 11:e1005203
142. Mozzi A, Pontremoli C, Forni D, Clerici M, Pozzoli U, et al. 2015. OASes and STING: adaptive evolution in concert. Genome Biol. Evol. 7:1016-32
143. Lemos de Matos A, McFadden G, Esteves PJ. 2013. Positive evolutionary selection on the RIG-I-like receptor genes in mammals. PLOS ONE 8:e81864
144. Patel MR, Loo YM, Horner SM, Gale M Jr., Malik HS. 2012. Convergent evolution of escape from hepaciviral antagonism in primates. PLOS Biol. 10:e1001282
145. Elde NC, Child SJ, Geballe AP, Malik HS. 2009. Protein kinase R reveals an evolutionary model for defeating viral mimicry. Nature 457:485-89
146. Compton AA, Malik HS, Emerman M. 2013. Host gene evolution traces the evolutionary history of ancient primate lentiviruses. Philos. Trans. R. Soc. Lond. B 368:20120496
147. Kaiser SM, Malik HS, Emerman M. 2007. Restriction of an extinct retrovirus by the human TRIM5a antiviral protein. Science 316:1756-58
148. Hochberg MC. 1997. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40:1725
149. Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, et al. 2007. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 39:1065-67
150. Namjou B, Kothari PH, Kelly JA, Glenn SB, Ojwang JO, et al. 2011. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 12:270-79
151. Danchenko N, Satia JA, Anthony MS. 2006. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15:308-18
152. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. 2010. Epidemiology of type 1 diabetes. Endocrinol. Metab. Clin. North Am. 39:481-97
153. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, et al. 1992. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 35:311-18
154. Risch N, Merikangas K. 1996. The future of genetic studies of complex human diseases. Science 273:1516-17
155. Anderson MS, Casanova JL. 2015. More than meets the eye: monogenic autoimmunity strikes again. Immunity 42:986-88
156. Cavalli-Sforza LL, Feldman MW. 2003. The application of molecular genetic approaches to the study of human evolution. Nat. Genet. 33(Suppl.):266-75
157. McClellan J, King MC. 2010. Genetic heterogeneity in human disease. Cell 141:210-17
158. Sun C, Molineros JE, Looger LL, Zhou XJ, Kim K, et al. 2016. High-density genotyping of immunerelated loci identifies new SLE risk variants in individuals with Asian ancestry. Nat. Genet. 48:323-30
159. Crow YJ. 2011. Lupus: how much "complexity" is really (just) genetic heterogeneity? Arthritis Rheum. 63:3661-64
160. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. PNAS 100:2610-15
161. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, et al. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711-23
162. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. 2005. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat. Med. 11:85-89
163. James JA, Harley JB, Scofield RH. 2006. Epstein-Barr virus and systemic lupus erythematosus. Curr. Opin. Rheumatol. 18:462-67
164. Gratama JW, Ernberg I. 1995. Molecular epidemiology of Epstein-Barr virus infection. Adv. Cancer Res. 67:197-255
165. Merrill JT, Buyon JP, Utset T. 2014. A 2014 update on the management of patients with systemic lupus erythematosus. Semin. Arthritis Rheum. 44:e1-2
166. Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, et al. 2016. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165:1548-50
167. Borba HH, Funke A, Wiens A, Utiyama SR, Perlin CM, Pontarolo R. 2016. Update on biologic therapies for systemic lupus erythematosus. Curr. Rheumatol. Rep. 18:44
168. Ablasser A, Hemmerling I, Schmid-Burgk JL, Behrendt R, Roers A, Hornung V. 2014.TREX1deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. J. Immunol. 192:5993-97
169. Sharma S, Campbell AM, Chan J, Schattgen SA, Orlowski GM, et al. 2015. Suppression of systemic autoimmunity by the innate immune adaptor STING. PNAS 112:E710-17